Pipeline

PBF-999

Novel dual Phosphodiesterase 10 (PDE-10) and adenosine A2a inhibitor for the treatment of rare metabolic diseases. A pivotal phase III trial in Prader-Willi syndrome patients is planned to start 2026.

PBF-1129

Potent and selective adenosine A2b receptor antagonist as first in class oral treatment for Idiopathic Pulmonary Fibrosis and lung cancer. Phase I clinical trials in healthy volunteers and a Phase IB trial in NSCLC have been completed.

PBF-1650

Potent and selective, orally bioavailable adenosine A3 receptor antagonist for the treatment of rare autoimmune diseases as Lowe Syndrome. Phase I studies in healthy volunteers have been completed.

PBF-680

Potent, non-BBB permeable, adenosine A1 receptor antagonist as a first in class oral treatment for rare eosinophilic diseases. The compound has clinically demonstrated its ability to reduce circulating eosinophils in patients with asthma and COPD.

PBF-677

Potent and selective, GI-restricted adenosine A3 receptor antagonist as first in class oral treatment for rare GI-diseases like EoE. Phase I in healthy volunteers and a POC trial in ulcerative colitis patients have been completed.

PBF-509

Potent, non-furan containing adenosine A2A receptor antagonist (super-caffeine) for as novel treatment for narcolepsy. The compound has completed Phase I in HV and several trials in cancer patients.